Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Programmed death‐ligand 1 (PD‐L1) expression status is inadequate for indicating nivolumab in patients with non–small cell lung cancer (NSCLC). Because the baseline advanced lung cancer inflammation index (ALI) is reportedly associated with patient outcomes, we investigated whether the pretreatment...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Med
Hauptverfasser: Shiroyama, Takayuki, Suzuki, Hidekazu, Tamiya, Motohiro, Tamiya, Akihiro, Tanaka, Ayako, Okamoto, Norio, Nakahama, Kenji, Taniguchi, Yoshihiko, Isa, Shun‐ichi, Inoue, Takako, Imamura, Fumio, Atagi, Shinji, Hirashima, Tomonori
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Clinical Cancer Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5773945/
https://ncbi.nlm.nih.gov/pubmed/29150906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1234
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge